This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-26. Anything still debated is marked as such rather than presented as settled.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
"The IDO-like myoglobin is unexpectedly widely distributed among gastropodic molluscs, such as Sulculus, Nordotis, Battilus, Omphalius and Chlorostoma." The hemocyanin from arthropods and molluscs evolved from different ancestors, tyrosinase and insect storage proteins, respectively. They have different molecular weight and structure. However, the proteins both use copper binding sites to transport oxygen. The hexokinase, ribokinase, and galactokinase families of sugar kinases have similar enzymatic functions of sugar phosphorylation, but they evolved from three distinct nonhomologous families since they all have distinct three-dimensional folding and their conserved sequence patterns are strikingly different. Hemoglobins in jawed vertebrates and jawless fish evolved independently. The oxygen-binding hemoglobins of jawless fish evolved from an ancestor of cytoglobin which has no oxygen transport function and is expressed in fibroblast cells. Toxic agent, serine protease BLTX, in the venom produced by two distinct species, the North American short-tailed shrew (Blarina brevicauda) and the Mexican beaded lizard, undergo convergent evolution. Although their structures are similar, it turns out that they increased the enzyme activity and toxicity through different way of structure changes. These changes are not found in the other non-venomous reptiles or mammals. Another toxin BgK, a K+ channel-blocking toxin from the sea anemone Bunodosoma granulifera and scorpions adopt distinct scaffolds and unrelated structures, however, they have similar functions.
The manufacture of immunoglobulins requires recombinase enzymes derived from the recombination activating genes RAG-1 and RAG-2. These enzymes are involved in the first stage of V(D)J recombination, the process by which segments of a B cell or T cell's DNA are rearranged to create a new T cell receptor or B cell receptor (and, in the B cell's case, the template for antibodies).Certain mutations of the RAG-1 or RAG-2 genes prevent V(D)J recombination, causing SCID.
== Changes during ontogeny == In the rat blood plasma, the GPx-3 activity is low during the first two weeks after birth and rapidly increasing during transition from milk nutrition to solid food. Aging is accompanied by decrease in GPx-3 activity: in the blood plasma of rats it occurs around 23-26 months of age.
== History == The US Food and Drug Administration (FDA) approved lebrikizumab based on evidence from three clinical trials (J2T-DM-KGAB, J2T-DM-KGAC, and J2T-DM-KGAD) of 1,062 participants aged twelve years of age and older with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The three trials were randomized, double-blind, placebo-controlled, and parallel group studies. Two trials were designed to evaluate the efficacy and safety of lebrikizumab as a monotherapy and one trial was designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid treatment. The trials were conducted at 223 of sites in 16 countries including Australia, Bulgaria, Canada, Estonia, France, Germany, Latvia, Lithuania, Mexico, Poland, Singapore, South Korea, Spain, Taiwan, Ukraine, and the United States. The trials enrolled 508 participants in the United States and 554 participants outside the United States.
Sources: en.wikipedia.org
=== Career in the United States === On G. I. Taylor's advice and recommendation, Dyson moved to the United States in 1947 as a Commonwealth Fellow for postgraduate study with Hans Bethe at Cornell University (1947–1948). There he made the acquaintance of Richard Feynman. Dyson recognized the brilliance of Feynman and worked with him. He then moved to the Institute for Advanced Study (1948–1949), before returning to England (1949–51), where he was a research fellow at the University of Birmingham. In 1949, Dyson demonstrated the equivalence of two formulations of quantum electrodynamics (QED): Richard Feynman's diagrams and the operator method developed by Julian Schwinger and Shin'ichirō Tomonaga. He was the first person after their creator to appreciate the power of Feynman diagrams and his paper written in 1948 and published in 1949 was the first to make use of them. He said in that paper that Feynman diagrams were not just a computational tool but a physical theory and developed rules for the diagrams that completely solved the renormalization problem. Dyson's paper and his lectures presented Feynman's theories of QED in a form that other physicists could understand, facilitating the physics community's acceptance of Feynman's work. J. Robert Oppenheimer, in particular, was persuaded by Dyson that Feynman's new theory was as valid as Schwinger's and Tomonaga's. Also in 1949, in related work, Dyson invented the Dyson series. It was this paper that inspired John Ward to derive his celebrated Ward–Takahashi identity.
=== Pharmacology === Preclinical and early clinical pharmacology studies characterized insulin icodec as a basal insulin analogue. The molecular modifications were intended to create an albumin-bound circulating depot, while preserving insulin receptor-mediated metabolic activity and limiting mitogenic activity relative to human insulin.
The melanocortins are a family of neuropeptide hormones which are the ligands of the melanocortin receptors. The melanocortin system consists of melanocortin receptors, ligands, and accessory proteins. The genes of the melanocortin system are found in chordates. Melanocortins were originally named so because their earliest known function was in melanogenesis. It is now known that the melanocortin system regulates diverse functions throughout the body, including inflammatory response, fibrosis, melanogenesis, steroidogenesis, energy homeostasis, sexual function, and exocrine gland function. There are four endogenous melanocortin agonists which are derived from post-transcriptional processing of the precursor molecule proopiomelanocortin (POMC). They are adrenocorticotropic hormone (ACTH), α-melanocyte stimulating hormone (MSH), β-MSH, and γ-MSH. In addition to agonists which activate melanocortin receptors, there are two antagonists which inhibit receptor activity, agouti-signaling protein (ASIP) and agouti-related protein (AgRP). Lastly, the ligand β-defensin 3 acts as a neutral melanocortin receptor antagonist.
Sources: en.wikipedia.org
== Formulations == The term dosage form may also sometimes refer only to the pharmaceutical formulation of a drug product's constituent substances, without considering its final configuration as a consumable product (e.g., capsule, patch, etc.). Due to the somewhat ambiguous nature and overlap of these terms within the pharmaceutical industry, caution is advisable when discussing them with others who may interpret the terminology differently.
=== Mechanical stimulation === Mechanical stimulation of angiogenesis is not well characterized. There is a significant amount of controversy with regard to shear stress acting on capillaries to cause angiogenesis, although current knowledge suggests that increased muscle contractions may increase angiogenesis. This may be due to an increase in the production of nitric oxide during exercise. Nitric oxide results in vasodilation of blood vessels. Beyond fluid shear stress, the water channel AQP1 contributes to the mechanical expansion of the cell membrane during migration. By facilitating localized water influx at the leading edge, AQP1 creates the hydrostatic pressure necessary to drive membrane protrusions, which is a critical physical step in the formation of new vascular sprouts.
== Structural studies == As of late 2007, 11 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1EJ2, PDB: 1GZU, PDB: 1HYB, PDB: 1KKU, PDB: 1KQN, PDB: 1KQO, PDB: 1KR2, PDB: 1M8F, PDB: 1M8G, PDB: 1M8J, and PDB: 1M8K.
IBA Lifesciences is a biotechnology company providing products and custom specific services for life science applications in academia and industry worldwide. IBA focusses on two business segments: cell selection and protein purification. The company is the original manufacturer and supplier of the Strep-tag/Strep-Tactin technology, an affinity chromatography system developed for protein purification. The method is based on one of the strongest non-covalent interactions in nature, which is the interaction of biotin to streptavidin. An intrinsic binding affinity of the Strep-tag towards Strep-Tactin results in a highly specific interaction, which enables the isolation and purification of sensitive proteins in a native state as wells as intact protein complexes, respectively. The technology was patented by the Max Planck Society (former “Garching Innovations”) and later assigned to IBA. Recently, the method was further developed to be used for cell selection from whole blood or other single cell suspensions.
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.